Abstract
Breast cancer is a disease that has plagued many women globally. The rapid rise in the incidence rate has prompted the rigorous search to understand its etiology and find better management strategies for this disease. Metallothionein (MT) belongs to a family of metal-binding proteins where dysregulated expression of this protein has been observed in invasive breast ductal carcinomas. Since its discovery in equine kidney, functions of MT have extended beyond the initial role of heavy metal detoxification to promoting tumorigenesis. MT, which was reported to be highly expressed in many tumors including breast cancers, is known to regulate key processes such as cell proliferation, apoptosis and even chemoresistance. In this patent review, we shall evaluate the roles of 10 functional isoforms of MT in breast neoplasia and discuss the utility of MT isoforms as biomarkers for prognosis. Strategies targeting MT for treatment could provide alternatives to overcome this dreaded disease which has claimed the lives of many women.
Keywords: Biomarker, breast cancer, chemoresistance, metallothionein, molecular therapy, MT-1E, MT-2A, MT-3, tumorigenesis, mammary gland
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Volume: 6 Issue: 2
Author(s): Yiyang Lai, George W.-C. Yip and Boon-Huat Bay
Affiliation:
Keywords: Biomarker, breast cancer, chemoresistance, metallothionein, molecular therapy, MT-1E, MT-2A, MT-3, tumorigenesis, mammary gland
Abstract: Breast cancer is a disease that has plagued many women globally. The rapid rise in the incidence rate has prompted the rigorous search to understand its etiology and find better management strategies for this disease. Metallothionein (MT) belongs to a family of metal-binding proteins where dysregulated expression of this protein has been observed in invasive breast ductal carcinomas. Since its discovery in equine kidney, functions of MT have extended beyond the initial role of heavy metal detoxification to promoting tumorigenesis. MT, which was reported to be highly expressed in many tumors including breast cancers, is known to regulate key processes such as cell proliferation, apoptosis and even chemoresistance. In this patent review, we shall evaluate the roles of 10 functional isoforms of MT in breast neoplasia and discuss the utility of MT isoforms as biomarkers for prognosis. Strategies targeting MT for treatment could provide alternatives to overcome this dreaded disease which has claimed the lives of many women.
Export Options
About this article
Cite this article as:
Lai Yiyang, W.-C. Yip George and Bay Boon-Huat, Targeting Metallothionein for Prognosis and Treatment of Breast Cancer, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489211795328495
DOI https://dx.doi.org/10.2174/157489211795328495 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and Antitumor Assessment of Phenylureas Bearing 5-Fluoroindolin-2-one Moiety
Medicinal Chemistry Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Stem Cell Therapies
Recent Patents on Regenerative Medicine DNA Methylation and Breast Cancer
Current Genomics ACO Inspired Computer-aided Detection/Diagnosis (CADe/CADx) Model for Medical Data Classification
Recent Patents on Computer Science On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Advances in the Discovery of Anthraquinone-Based Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Rapid Fluorimetric Quantitation of Ibandronate by Coupling Quantum Dots and Multicommutated Flow Injection Analysis
Current Pharmaceutical Analysis Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology lncRNA HOTAIR, HOXC11 and HOXC12 Gene Expressions are Upregulated in CaCo2 Cells Treated with P31-43 Toxic Peptide
Current Signal Transduction Therapy Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Role of Sigma Receptors in Methamphetamine-Induced Neurotoxicity
Current Neuropharmacology Natural Plant Extracts as Potential Therapeutic Agents for the Treatment of Cancer
Current Topics in Medicinal Chemistry Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry PCL/PEG Copolymeric Nanoparticles: Potential Nanoplatforms for Anticancer Agent Delivery
Current Drug Targets Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Folate Deficiency and Aberrant Expression of DNA Methyltransferase 1 were Associated with Cervical Cancerization
Current Pharmaceutical Design